Aptose Biosciences (OTC: APTOF) is a clinical-stage biotechnology company focused on developing targeted cancer therapies. The company generates no product revenue; operations are funded through equity financing and debt facilities, primarily a series of credit advances from strategic partner Hanmi. As of December 31, 2025, Aptose had drawn a total of $20.4 million across the Hanmi Facility Agreement and Amended Facility Agreement, with a Second Amended Facility Agreement providing up to an additional $11.1 million through May 31, 2026. The company reported a net loss of $25.5 million for the year ended December 31, 2025, an accumulated deficit of $566.4 million as of December 31, 2025, and cash and cash equivalents of $4.1 million as of that date. Total R&D expenses were $11.3 million for the year ended December 31, 2025, with the lead program, tuspetinib, accounting for $7.9 million of that spend. Aptose is incorporated in Canada and files with the SEC as a domestic issuer on Form 10-K.

Revenue model

Aptose generates no product revenue as of the 10-K filed March 31, 2026. Operations are funded through equity issuances and debt advances from Hanmi under a series of facility agreements. No payments from strategic partners beyond the Hanmi facility were disclosed.

Products and services

Lead drug candidate: tuspetinib, a targeted oncology therapeutic in clinical development. Active clinical studies include the TUSCANY study and the concluded APTIVATE clinical trial (as of fiscal year ended December 31, 2025). Program costs for tuspetinib were $7.9 million for the year ended December 31, 2025.

Customers and end markets

No commercial customers. End market is oncology, targeting cancer indications. Clinical-stage only as of December 31, 2025.

Value-chain role

Early-stage drug developer. Relies on contract research organizations (CROs) for clinical trial execution. No manufacturing or commercial sales infrastructure disclosed.

Geographic exposure

Incorporated and headquartered in Canada. Regulatory submissions described under both U.S. FDA and Canadian Health Canada frameworks.

Competitors

Established and emerging pharmaceutical companies with chemotherapeutic agents, Monoclonal antibody developers, Small molecule oncology drug developers, Immunotherapy and vaccine developers targeting cancer

Source: SEC 10-K, filed 2026-03-31

Industry: Biological Products, (No Diagnostic Substances) Peers: Alpha Compute Corp ESSA Pharma Inc. Xenon Pharmaceuticals Inc